Shares in an leading ASX-listed biotech have lost nearly all of their value after its lead drug candidate failed as a lung cancer treatment.
Immutep shares had plunged 90 per cent to 4 cents near midday on Friday, taking its market capitalisation from over $500 million to just $52 million - far less than the value of Immutep's bank account.
